Compounds / GH Axis / Ipamorelin

Ipamorelin

Ipamorelin (Selective Growth Hormone Secretagogue — Pentapeptide)
GH AxisWell ResearchedFDA: Not approvedWADA: PROHIBITED — Category S2

Overview

Most selective GH secretagogue studied. Phase II clinical trial for postoperative ileus (GI motility). Best combined with CJC-1295 for synergistic GH pulse amplification.

Mechanism of Action

Selective GHS-R1a agonist. Stimulates pulsatile GH release. NO cortisol/prolactin/aldosterone elevation. Does not desensitize GH secretagogue receptors. Half-life ~1.5–2.5 hours. GH peak ~40 min post-injection.

Pharmacokinetics

Half-life
2 hrs
Peak (Tmax)
40 min
Cleared
~10 hrs

Molecular Profile

Molecular weight
711.85 Da
CAS number
170851-70-4
Type
Growth hormone secretagogue
Length
5 amino acids

Key Research Findings

Selective GH release; no cortisol/prolactin; no receptor desensitization; synergistic with CJC-1295.

Published Research

Eur J Endocrinol (1998)
Raun K et al. Ipamorelin, the first selective growth hormone secretagogue
View source
Int J Colorectal Dis (2014)
Phase II clinical trial: Ipamorelin for postoperative ileus
View source

Related GH Axis Compounds

CJC-1295 (No DAC)CJC-1295 (DAC)SermorelinTesamorelinGHRP-2GHRP-6
Clinical Guidance

Research data is not a treatment plan. If you are considering Ipamorelin, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Ipamorelin? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals